FDA fast-tracks Halia’s promising new treatment for bone marrow disorder (opens in new tab)

Halia Therapeutics announced that the U.S. Food and Drug Administration has granted Fast Track designation to ofirnoflast (HT-6184) for the treatment of adult patients with lower-risk myelodysplastic syndromes. Fast Track status is intended to facilitate development and expedite review of therapies for serious conditions and can enable more frequent FDA interactions and eligibility for regulatory […] The post appeared first on <a href="